Autologous tumor-infiltrating lymphocyte (TIL) therapy in which a patient’s tumor-resident T cells are expanded ex vivo and reinfused to mediate TCR-dependent cytotoxicity and cytokine release against tumor/HPV antigens, aiming to overcome tumor microenvironment immunosuppression.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are reinfused to recognize tumor/HPV antigens via native TCRs and mediate antitumor effects through cytotoxic killing (perforin/granzyme) and cytokine release (e.g., IFN-γ), aiming to overcome tumor microenvironment immunosuppression.
Autologous TILs recognize HPV E7-derived peptide presented on MHC via native TCRs and directly kill target cells through perforin/granzyme-mediated apoptosis (and Fas/FasL), with supportive cytokine release.
Autologous tumor-infiltrating lymphocyte (TIL) therapy in which a patient’s tumor-resident T cells are expanded ex vivo and reinfused to mediate TCR-dependent cytotoxicity and cytokine release against tumor/HPV antigens, aiming to overcome tumor microenvironment immunosuppression.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are reinfused to recognize tumor/HPV antigens via native TCRs and mediate antitumor effects through cytotoxic killing (perforin/granzyme) and cytokine release (e.g., IFN-γ), aiming to overcome tumor microenvironment immunosuppression.
Infused TILs recognize neoantigen peptide–MHC via native TCRs and kill target cells through perforin/granzyme-mediated apoptosis (with supportive cytokine effects).
Autologous tumor-infiltrating lymphocyte (TIL) therapy in which a patient’s tumor-resident T cells are expanded ex vivo and reinfused to mediate TCR-dependent cytotoxicity and cytokine release against tumor/HPV antigens, aiming to overcome tumor microenvironment immunosuppression.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are reinfused to recognize tumor/HPV antigens via native TCRs and mediate antitumor effects through cytotoxic killing (perforin/granzyme) and cytokine release (e.g., IFN-γ), aiming to overcome tumor microenvironment immunosuppression.
Adoptively transferred TILs recognize tumor-associated self-antigen peptides presented on MHC via native TCRs and directly kill target cells through perforin/granzyme-mediated cytolysis (and Fas–FasL apoptosis), with cytokine support.
Autologous tumor-infiltrating lymphocyte (TIL) therapy in which a patient’s tumor-resident T cells are expanded ex vivo and reinfused to mediate TCR-dependent cytotoxicity and cytokine release against tumor/HPV antigens, aiming to overcome tumor microenvironment immunosuppression.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are reinfused to recognize tumor/HPV antigens via native TCRs and mediate antitumor effects through cytotoxic killing (perforin/granzyme) and cytokine release (e.g., IFN-γ), aiming to overcome tumor microenvironment immunosuppression.
Infused TILs recognize HPV E6/E7 peptides via native TCRs on antigen-presenting tumor cells and induce apoptosis via perforin/granzyme cytolysis (and Fas–FasL), supported by cytokines such as IFN-γ.
Oral small-molecule BCL-2 inhibitor that blocks anti-apoptotic BCL-2 to trigger mitochondrial apoptosis in AML blasts; given in 28-day cycles post-allogeneic HCT and may continue as monotherapy.
Selective oral BCL-2 inhibitor (BH3 mimetic) that binds the BH3-binding groove of anti-apoptotic BCL-2, neutralizing its pro-survival function and freeing pro-apoptotic effectors to trigger mitochondrial outer membrane permeabilization and caspase-dependent apoptosis in BCL-2–dependent AML cells; spares BCL-XL relative to navitoclax, reducing thrombocytopenia.
Venetoclax binds and inhibits anti-apoptotic BCL-2, freeing pro-apoptotic effectors (e.g., BAX/BAK) to induce mitochondrial outer membrane permeabilization, caspase activation, and intrinsic apoptosis in BCL-2–dependent cells.